SG11201906666QA - Methods of preparing cytotoxic benzodiazepine derivatives - Google Patents
Methods of preparing cytotoxic benzodiazepine derivativesInfo
- Publication number
- SG11201906666QA SG11201906666QA SG11201906666QA SG11201906666QA SG11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- english
- applicant
- pct
- rule
- Prior art date
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title abstract 2
- 230000001472 cytotoxic effect Effects 0.000 title abstract 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title 1
- 150000001557 benzodiazepines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/16—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/19—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450270P | 2017-01-25 | 2017-01-25 | |
| PCT/US2018/014956 WO2018140435A1 (en) | 2017-01-25 | 2018-01-24 | Methods of preparing cytotoxic benzodiazepine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906666QA true SG11201906666QA (en) | 2019-08-27 |
Family
ID=61189535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906666QA SG11201906666QA (en) | 2017-01-25 | 2018-01-24 | Methods of preparing cytotoxic benzodiazepine derivatives |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10385071B2 (pl) |
| EP (2) | EP3573948B1 (pl) |
| JP (3) | JP7066725B2 (pl) |
| KR (2) | KR20230005410A (pl) |
| CN (3) | CN116102615A (pl) |
| AU (3) | AU2018213202B2 (pl) |
| CA (1) | CA3050262A1 (pl) |
| DK (1) | DK3573948T3 (pl) |
| ES (1) | ES2935346T3 (pl) |
| FI (1) | FI3573948T3 (pl) |
| HR (1) | HRP20230002T1 (pl) |
| HU (1) | HUE060746T2 (pl) |
| IL (3) | IL293645A (pl) |
| LT (1) | LT3573948T (pl) |
| PL (1) | PL3573948T3 (pl) |
| PT (1) | PT3573948T (pl) |
| RS (1) | RS63871B1 (pl) |
| RU (2) | RU2021138005A (pl) |
| SG (1) | SG11201906666QA (pl) |
| SI (1) | SI3573948T1 (pl) |
| SM (1) | SMT202300001T1 (pl) |
| TW (3) | TW202400551A (pl) |
| WO (1) | WO2018140435A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230002T1 (hr) | 2017-01-25 | 2023-02-17 | Immunogen, Inc. | Postupci pripreme citotoksičnih derivata benzodiazepina |
| CA3119358A1 (en) | 2018-11-12 | 2020-05-22 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| IL283047B2 (en) | 2018-11-12 | 2024-04-01 | Immunogen Inc | Methods for preparing cytotoxic benzodiazepine derivatives |
| TW202102506A (zh) * | 2019-03-29 | 2021-01-16 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
| CN119486758A (zh) | 2022-06-30 | 2025-02-18 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9018601D0 (en) | 1990-08-24 | 1990-10-10 | Fujisawa Pharmaceutical Co | Tricyclic compounds |
| AP4012A (en) | 2010-12-21 | 2017-01-22 | Janssen Pharmaceutica Nv | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES |
| SMT201900181T1 (it) * | 2011-02-15 | 2019-05-10 | Immunogen Inc | Metodi di preparazione di coniugati |
| MX2017009145A (es) * | 2015-01-14 | 2017-11-22 | Bristol Myers Squibb Co | Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso. |
| KR20240063203A (ko) * | 2015-06-29 | 2024-05-09 | 이뮤노젠 아이엔씨 | 항-cd123 항체 및 이들의 접합체와 유도체 |
| EP3325483B1 (en) * | 2015-07-21 | 2019-10-02 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| HRP20230002T1 (hr) | 2017-01-25 | 2023-02-17 | Immunogen, Inc. | Postupci pripreme citotoksičnih derivata benzodiazepina |
-
2018
- 2018-01-24 HR HRP20230002TT patent/HRP20230002T1/hr unknown
- 2018-01-24 RS RS20221193A patent/RS63871B1/sr unknown
- 2018-01-24 ES ES18704352T patent/ES2935346T3/es active Active
- 2018-01-24 CN CN202310124604.6A patent/CN116102615A/zh active Pending
- 2018-01-24 SG SG11201906666QA patent/SG11201906666QA/en unknown
- 2018-01-24 HU HUE18704352A patent/HUE060746T2/hu unknown
- 2018-01-24 RU RU2021138005A patent/RU2021138005A/ru unknown
- 2018-01-24 EP EP18704352.6A patent/EP3573948B1/en active Active
- 2018-01-24 AU AU2018213202A patent/AU2018213202B2/en not_active Ceased
- 2018-01-24 PL PL18704352.6T patent/PL3573948T3/pl unknown
- 2018-01-24 SI SI201830832T patent/SI3573948T1/sl unknown
- 2018-01-24 TW TW112117953A patent/TW202400551A/zh unknown
- 2018-01-24 CN CN201880008141.4A patent/CN110225904B/zh active Active
- 2018-01-24 US US15/878,991 patent/US10385071B2/en active Active
- 2018-01-24 DK DK18704352.6T patent/DK3573948T3/da active
- 2018-01-24 IL IL293645A patent/IL293645A/en unknown
- 2018-01-24 KR KR1020227044421A patent/KR20230005410A/ko not_active Abandoned
- 2018-01-24 JP JP2019540404A patent/JP7066725B2/ja active Active
- 2018-01-24 EP EP22199432.0A patent/EP4148044A1/en not_active Withdrawn
- 2018-01-24 PT PT187043526T patent/PT3573948T/pt unknown
- 2018-01-24 LT LTEPPCT/US2018/014956T patent/LT3573948T/lt unknown
- 2018-01-24 TW TW111114178A patent/TWI805325B/zh active
- 2018-01-24 CA CA3050262A patent/CA3050262A1/en active Pending
- 2018-01-24 KR KR1020197024738A patent/KR102480594B1/ko active Active
- 2018-01-24 RU RU2019125133A patent/RU2762891C2/ru active
- 2018-01-24 IL IL287405A patent/IL287405B/en unknown
- 2018-01-24 SM SM20230001T patent/SMT202300001T1/it unknown
- 2018-01-24 CN CN202310124650.6A patent/CN116554262A/zh active Pending
- 2018-01-24 TW TW107102506A patent/TWI763771B/zh active
- 2018-01-24 WO PCT/US2018/014956 patent/WO2018140435A1/en not_active Ceased
- 2018-01-24 FI FIEP18704352.6T patent/FI3573948T3/fi active
-
2019
- 2019-06-17 US US16/442,718 patent/US10844078B2/en active Active
- 2019-07-22 IL IL268213A patent/IL268213B/en unknown
-
2020
- 2020-10-22 US US17/077,688 patent/US11390633B2/en active Active
-
2022
- 2022-03-07 AU AU2022201572A patent/AU2022201572B2/en not_active Ceased
- 2022-04-27 JP JP2022072946A patent/JP7400005B2/ja active Active
- 2022-06-15 US US17/841,026 patent/US11981687B2/en active Active
-
2023
- 2023-12-06 JP JP2023205788A patent/JP2024028860A/ja not_active Withdrawn
-
2024
- 2024-02-21 AU AU2024201119A patent/AU2024201119A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201906666QA (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer |